Research programme: nuclear receptor modulators - Allergan

Drug Profile

Research programme: nuclear receptor modulators - Allergan

Alternative Names: AGN193198

Latest Information Update: 11 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Allergan
  • Class Small molecules
  • Mechanism of Action Cytoplasmic and nuclear receptor modulators; Retinoic acid receptor agonists; Retinoic acid receptor antagonists; Retinoid X receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Neutropenia

Most Recent Events

  • 24 Mar 2008 NRX 4204 has moved into clinical development
  • 18 May 2007 Vitae Pharmaceuticals sublicenses rights to this research programme to Quest Group International
  • 16 Aug 2005 Preclinical trials in Neutropenia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top